Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Gilead Sciences (NASDAQ:GILD), the $146.5 billion biotech giant whose stock has surged over 63% in the past year, reported that Chief Commercial Officer Johanna Mercier sold 25,300 shares of the company’s common stock on August 15, 2025, for approximately $3.3 million. The sales were executed at prices ranging from $118.5044 to $118.9686, near the stock’s 52-week high of $121.83.
On the same day, Mercier exercised options to acquire 25,300 shares of Gilead Sciences common stock at a price of $66.64 per share, for a total value of $1,666,000.
Following these transactions, Mercier directly owns 114,168 shares of Gilead Sciences.
In other recent news, Gilead Sciences has seen several updates following its second-quarter earnings report. The company reported total sales of $7.1 billion, with earnings per share at $1.97, which BofA Securities described as "good overall." Gilead also raised its full-year revenue guidance by $500 million, excluding its COVID-19 treatment Veklury, as noted by Cantor Fitzgerald. Analysts have adjusted their price targets for Gilead, reflecting these developments. Mizuho (NYSE:MFG) increased its target to $131, driven by higher sales estimates for Gilead’s anito-cel treatment. BofA Securities raised its target to $140, while TD Cowen adjusted its target to $115, citing strong HIV sales. Cantor Fitzgerald maintained its $129 target, emphasizing Gilead’s solid performance. RBC Capital also raised its target to $98, acknowledging strong results in key franchises. These changes highlight the company’s robust financial performance and strategic outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.